cut pt lower project
reduc pt old ebitda
new ebitda although
busi execut financi disappoint
project compani return growth come year
lower estim wake result guidanc reduct
reduc project due competit pressur disappoint uptak
complex gener due brand rebat strategi chang follow
revenue management rang adj ebitda
adj ep management ep rang
revenue adj ebitda
adj ep
valuat alreadi reflect busi challeng public
clearinghous valuat report aug titl ev/revenu metric week
biopharma comp clearinghous trade one lowest ev/rev
multipl global pharma-bio stock
project return modest growth forecast
compound-annual-growth-rate revenue ebitda ep next year
pressur on-going ex-u growth drive improv prospect
investor expect low board strateg review enhanc
sharehold valu view posit investor see obviou
path sharehold valu creation compani execut better
drive acceler revenu earn growth myl financi leverag
preclud meaning extern compani appear alreadi
effici cost structur look forward futur updat see
board offer surpris
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
pt base ebitda target multipl within
rang pt impli target price-to-earnings
project ebitda compound-annual-growth-rate ep compound-annual-growth-rate
ev/ebitda bull case ebitda
ev/ebitda bull case
ebitda
gener growth surpris upsid boost prospect new pipelin
driver moder us price pressur drive ebitda forecast
management pursu value-cr deal ev/ebitda increas
ev/ebitda base case ebitda
ev/ebitda base case ebitda
deliv modest growth includ acceler ex-u
busi segment continu deliv strong growth us gener price
headwind persist garner approv gadvair drive greater
confid abil capit high-hurdl gener opportun
ev/ebitda bear case
ev/ebitda bear case ebitda
ebitda
gener busi disappoint due competit pressur key new
launch delay face problemat govern investig
develop gener price environ worsen gadvair grestasi
launch delay ebitda forecast ev/ebitda multipl
contract
rate overweight
forecast solid growth prospect
revenu ebitda ep
encourag pipelin newsflow
benefit investor percept thu
expect garner approv
gadvair drive greater confid
abil capit high-hurdl gener
gener industri myl-specif gener
gadvair grestasi
gcopaxon uptak competit
epipen trend competit
financi result guidanc updat
fda action new product applic
success new product launch
resolut investig litig
risk achiev price
us gener environ may
deterior due addit competit
due approv delay and/or increas
may result fine claim
ex-u busi may fall short
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
